Description: G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.
Home Page: www.g1therapeutics.com
GTHX Technical Analysis
700 Park Offices Drive
Research Triangle Park,
NC
27709
United States
Phone:
919 213 9835
Officers
| Name | Title |
|---|---|
| Mr. John E. Bailey Jr. | CEO, Pres & Director |
| Ms. Jennifer K. Moses CPA | Chief Financial Officer |
| Dr. Mark A. Velleca M.D., Ph.D. | Sr. Advisor & Director |
| Dr. Rajesh K. Malik Ch.B., M.B., M.D. | Chief Medical Officer and Sr. VP of R&D |
| Mr. Mark Avagliano | Chief Bus. Officer |
| Mr. Andrew Perry | Chief Commercial Officer |
| Mr. Terry L. Murdock | Chief Operating Officer |
| Mr. Alexander D. Smith M.S. | VP of Technical Operations |
| Dr. Jay C. Strum Ph.D. | Chief Scientific Officer |
| Mr. William C. Roberts | VP of Investor Relations & Corp. Communications |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.036 |
| Price-to-Sales TTM: | 6.4606 |
| IPO Date: | 2017-05-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 148 |